30 October 2019
Aortic Aneurysm Market Forecast 2020-2030: Forecasts and Analysis By Type (TAA, AAA), By Treatment (Open Surgical Repair, Endovascular Aneurysm Repair), By Product (Stent Graft, Catheter), By End Use (ASC, Hospital) and Geography, with Profiles of Leading Companies, with Profiles of Leading Companies report provides impartial Aortic Aneurysm sector analysis.
According to the report published by Visiongain, the Aortic Aneurysm market is forecast at USD 3.2 billion in 2020 and a CAGR of 8.7 percent is anticipated from 2020 to 2030. Increasing geriatric population, bad dietary habits and elevated incidence of cardiovascular diseases (CVDs) are some of the variables that fuel requirement for new thoracic and abdominal aneurysm restoration medicines and equipment that, in fact, are supposed to boost the industry. Smoking is also adding to the development of this industry, which has become a worldwide issue. In specific, low- and middle-income nations experience significant smoking issues owing to absence of knowledge of the damaging environmental impacts of smoking and related danger of creating aneurysm. Scenarios for legislative and reimbursement differ across areas.
Strict laws regulate fresh brand releases in developed countries, such as the U.S., to preserve product quality. However, the reimbursement situations are mostly favourable for the surgical therapy of aortic aneurysms. The mandatory Medicare scheme, supplied by the U.S. government, covers more than 70 percent of the complete therapy price. Flexible laws for medical devices in emerging nations such as China and India enable local producers to introduce low-cost products. On the other hand, lower reimbursements result in higher costs of treatments, which is a major factor restraining the market development in such regions. However, continuous advancements, in terms of technology, in endovascular surgical procedures is projected to augment the growth of the market over the next few years.
Aortic Aneurysm Market is witnessing Growth due to factors such as
According to information from Centers for Disease Control and Prevention (CDC), AAA is largely found in the ageing workforce (65 years and older). Furthermore, according to the 2015 Oxford Vascular research, 1.75.000 fatalities owing to AAA are recorded, among which 1 half of fatalities occur in males over the era of 65. With a increasing geriatric population, AAAs instances are anticipated to rise, pushing market growth for abdominal aortic aneurysm replacement systems. The key players profiled in the global abdominal aortic aneurysm repair devices market include Cook Medical Inc., Endologix, Inc., W. L. Gore & Associates, Inc., AbbVie Inc., Medtronic Plc., Cardinal Health Inc., Cardiatis S.A., C. R. Bard, Inc., Lombard Medical, Inc., and Terumo Corporation. Other prominent players in the value chain include WefernLife, Braile Biomdica, and MicroPort Scientific Corporation.
The North American abdominal aortic aneurysm repair equipment sector accounted for the largest share and is expected to proceed to dominate the worldwide business volume of abdominal aortic aneurysm repair equipment in the forecast period. This is ascribed to an increase in geriatric population, elevated acceptance rates of technologically sophisticated abdominal aortic aneurysm repair equipment and enhanced customer consciousness. Europe is ranked second in the market share of abdominal aortic aneurysm repair equipment. Asia-Pacific is anticipated to experience the greatest development rate, population growth, affordability increase, enhancement,
North America dominates the industry for abdominal aortic aneurysm repair (AAA) in 2019 and in the prediction period the pattern is the same. Well-established wellness infrastructure; the existence of important competitors; and rising atherosclerosis incidence are the main pushing considerations for this North American region industry. Due to increased knowledge of sophisticated therapy techniques; increased incidence of obese nurses; and the existence of emerging countries such as China and India, the Asian abdominal aortic aneurysm repair industry is set to expand at the largest CAGR during the forecast period.
Shift in Trends
Currently Available Custom-Made Devices
Broadly speaking, the most frequently used conventional endovascular aneurysm surgery (EVAR) and endovascular thoracic aneurysm surgery (TEVAR) systems are custom-made in some respects. Even though each personal element is specified in infra-renal EVAR or TEVAR, the unit produced in vitro is a composite of these parts into a full endograft that is custom-made for each person by some means. The exercise of mixing distinct parts from distinct instrument producers to accomplish a fix in the personal nurse is sometimes implemented off-label and goes one stage further with this "customization".
However, the term custom-made is used for the purposes of this article to describe specifically ordered endografts that are tailored to the anatomy of the individual patient and can not be achieved simply by combining standard devices available. In most cases, this will involve endovascular stent grafts used to treat side branches of the aorta (e.g., thoracoabdominal, juxtarenal, and suprarenal aneurysms) and aortic arch repair areas. Although customization will in some times only require getting the diameter bigger or lower or altering the endograft's general size. We address several producers of stent graft which on demand will provide tailored equipment.
The endovascular strategy is quickly becoming the favored abdominal aortic aneurysm therapy and is also becoming more accessible for thoracic aortic aneurysm therapy. Cleveland Clinic surgeons have helped develop these sophisticated aneurysm therapy methods During the previous 3 centuries, endovascular cure of aortic pathologies has become increasingly used. What began as a disruptive technology to treat infrarenal aneurysms with physician-made or -modified instruments has extended quickly into therapy choices including nearly every segment of the aorta, from the aortic valve to the iliac bifurcations.
Thoracic Aortic Aneurysm (TAA) and Abdominal Aortic Aneurysm (AAA) are segmented by form on the worldwide economy. The biggest section in 2018 was abdominal aortic aneurysm, which can be ascribed to the enhanced incidence of disease. In the lower abdominal part, AAA is more common, and most cases of AAA occur either in the lower abdomen's infrarenal or juxtarenal part. Collectively, the amount of infrarenal and juxtarenal interventions conducted is much greater by quantity relative to thoracic aneurysms. Low incidence of TAA and unavailability of sophisticated systems for its leadership by endovascular techniques can be ascribed to steady growth of the thoracic segment. However, this section is expected to acquire momentum during the forecast period with technological and item advances. For example, Castor obtained permission for its thoracic stent grafting scheme from China Food and Drug Administration (CFDA) in June 2017. It is the world's first stent graft intended concurrently for endovascular thoracic aorta leadership and large arch ships.
The industry was classified as Open Surgical Repair (OSR) and Endovascular Aneurysm Repair (EVAR) based on the sort of therapy. In 2018, the EVAR segment led the global market and is expected to witness the fastest CAGR over the estimated period of time. This development can be ascribed to the growing global acceptance of endovascular therapy combined with advances in technology, helping longer hospital visits and reduced morbidity connected with aortic aneurysm surgery. The OSR procedures are highly invasive and require a longer period of recovery compared to the endovascular method. However, for low-risk nurses with simpler anatomy, OSR is the only therapy choice accessible. Endovascular treatment is the method of choice for surgeons and can only be performed in high-risk patients with complex anatomies; if open-repair treatment is possible, it is not recommended to perform endovascular surgery.
The industry is divided into hospitals and Ambulatory Surgical Centers (ASCs) & clinics on the grounds of end-use. The section of clinics retained the biggest market share in 2019, while ASCs are expected to grow over the forecast period at the lowest CAGR. This is owing to the advantages that ASCs offer, such as decreased hospital stay and general cost of therapy. Moreover, increasing aortic aneurysm incidence, particularly in developed countries, and the need for timely therapy are probable to fuel the ASC section. However, the hospital segment is anticipated to continue to lead the market, as it is the most-preferred setting by physicians and vascular surgeons, especially in the developing region. The elaborate set up in hospitals enables treating complex cases that cannot be managed in ASCs.
Regional Market Analysis
Since the original therapy of easy infrarenal aortic aneurysms, the EVAR sector has evolved quickly. New systems presently enable the full aorta to be treated endovascularly, including difficult growing vessel regions such as the visceral aorta and the aortic arch. However, in these difficult aorta fields, the variation in anatomy needs comprehensive customization to enable personal graft development and therapy. In addition, the anatomy of the branch vessels is very varied. Preliminary information indicate that the result is crucial for long-term patentability and results when using lateral stems versus "easy" fenestrations and scallops to revascularize destination ships. These anatomic challenges have made the quest for readily available, standardized off-the-shelf devices difficult to bring into clinical practice.
The 2014 U.S. government implemented Screening Abdominal Aortic Aneurysms Very Effectively (SAAAVE) Act provides one free AAA testing for males who have smoked at least once in their lives and females with a family history of the disorder. In addition, elevated reimbursements in developed nations provided by banks are another variable that supports general market growth. For example, for nurses at danger, Medicare in the U.S. includes one abdominal aortic test. Due to technological advances and elevated incidence atherosclerosis, Europe is also expected to compensate for important business presence during the prediction era. International organisations like the National Health Service (NHS) and the United States. FDA, are collaborating to reduce aortic aneurysm occurrence.
For example, the NHS testing program for Public Health England in Europe is a domestic population testing program that helps define healthy people who may be at danger of creating aortic aneurysm. This, in effect, allows premature therapy and informed decision making. During the forecast period, Asia Pacific is anticipated to experience the highest CAGR due to the increasing geriatric population and incidence of cardiovascular diseases & hypertension, increased disposable revenue, and the development of health facilities.
Competition in the market
Some of the main businesses include Medtronic PLC; Endologix, Inc.; Gore Medical; and Cook Medical, Inc. The industry, however, has a bulk of mid-and small-scale firms. Mergers & purchases is one of the main approaches that most significant participants in the industry have embraced. Bolton Medical and Vascutek, for example, combined into a new company in April 2018 to enhance the place on the worldwide industry for aortic and vascular implants.
In April 2019, Lombard Medical Technologies GmbH and Lombard Medical Limited purchased stocks from Endovascular Technology Corp., a subsidiary of MicroPort Scientific Corp. MicroPort proceeded its partnership with Lombard with this purchase and commercialized its two stent-graft techniques-Aorfix and Altura. Cryolife Inc. purchased JOTEC later that year. However, national companies in each region, by offering low-priced stent grafts, place a strong contest on the global companies.
The antibiotics market was valued at US$44,567.3 million in 2022 and is projected to grow at a CAGR of 4.15% during the forecast period 2023-2033.
31 January 2023
The global Clinical Trial Supplies market was valued at US$ 2,617.7 million in 2022 and is projected to grow at a CAGR of 9.32% during the forecast period 2023-2033.
31 January 2023
The global Meningococcal Vaccines market was valued at US$3,268.6 million in 2022 and is projected to grow at a CAGR of 6.32% during the forecast period 2023-2033.
31 January 2023
The global Human Microbiome market was valued at US$186.8 million in 2022 and is projected to grow at a CAGR of 25% during the forecast period 2023-2033.